Richard B. Westkaemper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Richard B. Westkaemper has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Bryan L. Roth
Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599 USA
5 shared publicationsPhilip D. Mosier
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298 USA
5 shared publicationsJitesh R. Shah
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA
2 shared publicationsSrinivas Peddi
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA
2 shared publicationsDonna L. McGovern
Department of Medicinal Chemistry, P.O. Box 980540, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298-0540, USA
1 shared publicationGajanan K. Dewkar
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 410 N. 12th Street, PO Box 980540, Richmond, VA 23298-0540, USA
1 shared publication
Latest Publications
- 1 April 2010
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 28 (7) , 612-625
CoMFA analyses of C-2 position Salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity
- 1 April 2010
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 28 (7) , 612-625
CoMFA analyses of C-2 position Salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity
- 1 February 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (3) , 935-938
9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites
- 1 February 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (3) , 935-938
9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites
- 1 September 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 17 (18) , 6496-6504
Synthesis, structure–affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: Structural factors contributing to selectivity
- 1 September 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 17 (18) , 6496-6504
Synthesis, structure–affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: Structural factors contributing to selectivity
- 11 October 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (21) , 6808-6828
Potential Modes of Interaction of 9-Aminomethyl-9,10-dihydroanthracene (AMDA) Derivatives with the 5-HT2AReceptor: A Ligand Structure-Affinity Relationship, Receptor Mutagenesis and Receptor Modeling Investigation
The effects of 3-position substitution of 9-aminomethyl-9,10-dihydroanthracene (AMDA) on 5-HT2A receptor affinity were determined and compared to a parallel series of DOB-like 1-(2,5-dimethoxyphenyl)-2-aminopropanes substituted at the 4-position. The results were interpreted within the context of 5-HT2A receptor models that suggest that members of the DOB-like series can bind to the receptor in two distinct modes that correlate with the compounds’ functional activity. Automated ligand docking and molecular dynamics suggest that all of the AMDA derivatives, the parent of which is a 5-HT2A antagonist, bind in a fashion analogous to that for the sterically demanding antagonist DOB-like compounds. The failure of the F3406.52L mutation to adversely affect the affinity of AMDA and the 3-bromo derivative is consistent with the proposed modes of orientation. Evaluation of ligand−receptor complex models suggest that a valine/threonine exchange between the 5-HT2A and D2 receptors may be the origin of selectivity for AMDA and two substituted derivatives.
- 11 October 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (21) , 6808-6828
Potential Modes of Interaction of 9-Aminomethyl-9,10-dihydroanthracene (AMDA) Derivatives with the 5-HT2AReceptor: A Ligand Structure-Affinity Relationship, Receptor Mutagenesis and Receptor Modeling Investigation
The effects of 3-position substitution of 9-aminomethyl-9,10-dihydroanthracene (AMDA) on 5-HT2A receptor affinity were determined and compared to a parallel series of DOB-like 1-(2,5-dimethoxyphenyl)-2-aminopropanes substituted at the 4-position. The results were interpreted within the context of 5-HT2A receptor models that suggest that members of the DOB-like series can bind to the receptor in two distinct modes that correlate with the compounds’ functional activity. Automated ligand docking and molecular dynamics suggest that all of the AMDA derivatives, the parent of which is a 5-HT2A antagonist, bind in a fashion analogous to that for the sterically demanding antagonist DOB-like compounds. The failure of the F3406.52L mutation to adversely affect the affinity of AMDA and the 3-bromo derivative is consistent with the proposed modes of orientation. Evaluation of ligand−receptor complex models suggest that a valine/threonine exchange between the 5-HT2A and D2 receptors may be the origin of selectivity for AMDA and two substituted derivatives.
- 1 October 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (19) , 5268-5271
Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT2A receptor
- 1 October 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (19) , 5268-5271
Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT2A receptor